A recombinant form of human G-CSF, specifically the recombinant methionyl human G-CSF NEUPOGEN® (filgrastim), was initially approved with an indicated use to decrease the incidence of infection and reduce severe neutropenia. The gene discussed is CSF3; the disease is Decreased total neutrophil count.